Muhammed N Rahman is a pharmacist who is specialized in Oncology in New York, New York. Patients can reach him at 506 Malcolm X Blvd, New York or contact him on 212-939-1761. Active license number of Muhammed N Rahman is 030989 for Oncology in New York. Muhammed N Rahman is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Muhammed N Rahman speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Muhammed N Rahman
Specialization:
Oncology
Credentials:
B.S,B.S(PHARMACY)
Gender:
Male
Location:
506 Malcolm X Blvd, New York, New York, 10037-1802
Phone:
212-939-1761
Fax:
212-939-1759
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Muhammed N Rahman are as mentioned below.
NPI Number:
1023196425
NPI Enumeration Date:
02 Nov, 2006
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Muhammed N Rahman are as mentioned below.
Specialization
License Number
State
Status
Oncology
030989
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
221 Stone St, Elmont, New York
Zip:
11003-2240
Phone Number:
516-775-6853
Fax Number:
--
Patients can reach Muhammed N Rahman at 506 Malcolm X Blvd, New York, New York or can call on phone at 212-939-1761.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.